Here is what the page “Treasury Proposes Major Restrictions on U.S. Investment in Chinese Biotech, Licensing Deal” contains. Treasury Department has unveiled a proposal that would significantly curb American investment in Chinese biotechnology companies. The move, part of a broader effort to protect national security and maintain technological leadership, targets equity investments and certain transactions, though it notably carves out an exception for licensing agreements. firms could still strike licensing deals with Chinese biotechs, but direct financial backing would face new hurdles.
The proposal comes amid heightened tensions between Washington and Beijing over advanced technologies, with biotech increasingly seen as a strategic sector. Industry experts say the rules could reshape the flow of capital and collaboration in the global life sciences market, potentially slowing innovation while addressing security concerns. The Treasury will accept public comments before finalizing the regulations, leaving room for adjustments based on industry feedback. The full version stays on the original page, which this listing opens directly.